News

Oral minocycline was not associated with a decrease in GA enlargement over 24 months, compared with the run-in phase, in a recent phase 2 nonrandomized trial.

A post-AAD 2024 discussion on the importance of tailoring acne and rosacea management to individual patients’ needs, focusing more attention on diverse skin types and backgrounds.

In a landmark decision, the FDA has granted accelerated approval to resmetirom (Rezdiffra) for noncirrhotic NASH with moderate to advanced fibrosis.

The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heart failure by targeting the left ventricle.

Nesvategrast was safe and well tolerated but did not exhibit a statistically significant impact on the severity or progression of diabetic retinopathy in the phase 2 DR:EAM trial.

In this AAD 2024 interview, Bunick highlights several new findings on the use of topical isotretinoin for treatment of congenital ichthyosis.

On March 11, 2024, Acelyrin Inc. announced new positive data from clinical trial programs examining their IL-17A inhibitor izokibep in patients psoriatic arthritis and hidradenitis suppurativa.

Lindsey Venesky, PhD, discussed how a mental fitness vocal biomarker tool could identify mental health symptoms people might not even be aware of through their voice.

To acknowledge World Kidney Day, our latest episode of Crisis Point focuses on the stigma surrounding the use of HCV-positive donor kidneys amid the ongoing organ shortage crisis, with the perspective of a pair of experts and an HCV donor kidney recipient.

“Having a previous anxiety disorder before a crisis occurs can be a blessing” — a new study found therapy for anxiety before the COVID-19 pandemic helped individuals not have increased anxiety during and after the pandemic.

Results showed the cell-free DNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions.

New data show sensitization among children with allergic contact dermatitis may be significantly influenced by their age and gender, among other demographic details.

Saeed Mohammed, MD, MS, discusses maralixibat for pruritus in PFIC, describing how IBAT inhibitors have changed the way clinicians are able to treat cholestatic liver disease.

Iptacopan monotherapy improved hematologic outcomes in both anti-C5–treated patients with persistent anemia and those not treated with complement inhibitors across two phase 3 trials.

Alexis discusses clinical and demographic hurdles in treating skin of color for conditions like atopic dermatitis, and the potential of research like that being done in tapinarof cream 1%.

A new study suggests a next-generation stool DNA test from Exact Sciences has improved sensitivity for colorectal cancer and precancerous lesions but lower specificity than FIT.

In a registry-based analysis, more hospitalized children with SCD and COVID-19 had severe infection requiring supplemental oxygen, compared with the general population.

The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease is an update to the KDIGO 2012 CKD Guideline.

In an interview with HCPLive, Daniel Karlin, MD, discussed how their phase 2B trial demonstrated MM120’s durability through week 12 for the treatment of generalized anxiety disorder.

Now, 4 years since the start of the pandemic, how has sleep been impacted? Sleep experts provide their perspective.

New data from the Family Heart Foundation highlights low access to PCSK9 inhibitors due to insurance rejections, despite guidelines recommending their use for high-risk patients.

Treatment with DAA therapy at 3 years of age was associated with better health outcomes and cost savings versus deferring initiation to 6 years of age or older.

Both biologic-naïve and biologic-experience patients receiving guselkumab demonstrated significantly higher ACR20 when compared with ustekinumab.

The 2016 CDC guidelines led to significant decreases in opioid prescriptions and an increase in pain-related healthcare utilization for people with sickle cell disease.

Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis—and why it may be "disruptive in the treatment space."

Judith Ng-Cashin, MD discusses Novotech's recent Rheumatoid Arthritis - Global Clinical Trial Landscape report.

Alexis spoke in this AAD interview about his team’s results regarding lebrikizumab for adults and adolescents with moderate-to-severe atopic dermatitis and skin of color.

An analysis of an FDA adverse event database found thrombotic adverse events were more frequently reported with emicizumab than those of FVIII products.

A new study found women (1.64) had a greater hazard ratio of depression for CVD than men (1.39).

New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.